Clinical and inflammatory factors associated with body mass index in elderly patients with chronic obstructive pulmonary disease

Geriatrics and Gerontology International

Volumn 11, Issue 1, 2011, Pages 32-38

  Yuji, Higashimoto ^a,b   Toshiyuki, Yamagata ^a   Noritsugu, Honda ^a   Ryuji, Satoh ^a   Hiroyuki, Sano ^a   Takashi, Iwanaga ^a   Takayuki, Miyara ^a   Masato, Muraki ^a   Katsuyuki, Tomita ^a   Yuji, Tohda ^a   Kanji, Fukuda ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

1 antitrypsin; Body mass index; COPD; Emphysema; Inflammation

Indexed keywords

ALPHA 1 ANTITRYPSIN; C REACTIVE PROTEIN; FIBRINOGEN; GELATINASE B; INTERLEUKIN 6; INTERLEUKIN 8; LEUKOCYTE ELASTASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

AGED; AGING; ARTICLE; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LUNG EMPHYSEMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BODY MASS INDEX; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; HUMANS; INFLAMMATION; MALE; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX;

EID: 78650243076     PISSN: 14441586     EISSN: 14470594     Source Type: Journal    
DOI: 10.1111/j.1447-0594.2010.00629.x     Document Type: Article

References (42)

1. Landbo C, Prescott E, Lange P, Vestbo J, Almdal TP. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 1856-1861.
2. Congleton J. The pulmonary cachexia syndrome: aspects of energy balance. Proc Nutr Soc 1999; 58: 321-328.
3. Motohashi N, Kimura K, Ishii T et al. Emphysema on imaging is associated with quality of life in elderly patients with chronic obstructive pulmonary disease. Geriatr Gerontol Int 2010; 10: 17-24.
4. Moore JA, Angelillo VA. Equations for the prediction of resting energy expenditure in chronic obstructive lung disease. Chest 1988; 94: 1260-1263.
5. Rabinovich RA, Bastos R, Ardite E et al. Mitochondrial dysfunction in COPD patients with low body mass index. Eur Respir J 2007; 29: 643-650.
6. Pouw EM, Schols AM, Deutz NE, Wouters EF. Plasma and muscle amino acid levels in relation to resting energy expenditure and inflammation in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 158: 797-801.
7. Eid AA, Ionescu AA, Nixon LS et al. Inflammatory response and body composition in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 1414-1418.
8. Ogawa E, Nakano Y, Ohara T et al. Body mass index in male patients with COPD: correlation with low attenuation areas on CT. Thorax 2009; 64: 20-25.
9. Miniati M, Monti S, Stolk J et al. Value of chest radiography in phenotyping chronic obstructive pulmonary disease. Eur Respir J 2008; 31: 509-515.
10. Agusti AG, Noguera A, Sauleda J, Sala E, Pons J, Busquets X. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 347-360.
11. Wouters EF. The systemic face of airway diseases: the role of C-reactive protein. Eur Respir J 2006; 27: 877-879.
12. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004; 59: 574-580.
13. Higashimoto Y, Yamagata Y, Iwata T et al. Increased serum concentrations of tissue inhibitor of metalloproteinase-1 in COPD patients. Eur Respir J 2005; 25: 885-890.
14. Higashimoto Y, Yamagata Y, Taya S et al. Systemic inflammation in chronic obstructive pulmonary disease and asthma: similarities and differences. Respirology 2008; 13: 128-133.
15. Karadag F, Karul AB, Cildag O, Altun C, Gurgey O. Determinants of BMI in patients with COPD. Respirology 2004; 9: 70-75.
16. Karadag F, Kirdar S, Karul AB, Ceylan E. The value of C-reactive protein as a marker of systemic inflammation in stable chronic obstructive pulmonary disease. Eur J Intern Med 2008; 19: 104-108.
17. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163: 1256-1276.
18. Goddard PR, Nicholson EM, Laszlo G, Watt I. Computed tomography in pulmonary emphysema. Clin Radiol 1982; 33: 379-387.
19. Schols AM, Slangen J, Volovics L, Wouters EF. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1791-1797.
20. Agusti AG, Sauleda J, Miralles C et al. Skeletal muscle apoptosis and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166: 485-489.
21. Itoh T, Nagaya N, Yoshikawa M et al. Elevated plasma ghrelin level in underweight patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170: 879-882.
22. Wagner PD. Possible mechanisms underlying the development of cachexia in COPD. Eur Respir J 2008; 31: 492-501.
23. Van Helvoort HA, Heijdra YF, Thijs HM, Vina J, Wanten GJ, Dekhuijzen PN. Exercise-induced systemic effects in muscle-wasted patients with COPD. Med Sci Sports Exerc 2006; 38: 1543-1552.
24. Broekhuizen R, Grimble RF, Howell WM et al. Pulmonary cachexia, systemic inflammatory profile, and the interleukin 1beta -511 single nucleotide polymorphism. Am J Clin Nutr 2005; 82: 1059-1064.
25. Argiles JM, Lopez-Soriano J, Busquets S, Lopez-Soriano FJ. Journey from cachexia to obesity by TNF. Faseb J 1997; 11: 743-751.
26. Venembre P, Boutten A, Seta N et al. Secretion of alpha 1-antitrypsin by alveolar epithelial cells. FEBS Lett 1994; 346: 171-174.
27. Magielska-Zero D, Bereta J, Czuba-Pelech B, Pajdak W, Gauldie J, Koj A. Inhibitory effect of human recombinant interferon gamma on synthesis of acute phase proteins in human hepatoma Hep G2 cells stimulated by leukocyte cytokines, TNF alpha and IFN-beta 2/BSF-2/IL-6. Biochem Int 1988; 17: 17-23.
28. Needham M, Stockley RA. Alpha 1-antitrypsin deficiency. 3: clinical manifestations and natural history. Thorax 2004; 59: 441-445.
29. Seyama K. State of alpha1-antitrypsin deficiency in Japan. Respirology 2001; 6 (Suppl): S35-S38.
30. Engstrom G, Lind P, Hedblad B, Stavenow L, Janzon L, Lindgarde F. Effects of cholesterol and inflammation-sensitive plasma proteins on incidence of myocardial infarction and stroke in men. Circulation 2002; 105: 2632-2637.
31. Lind P, Engstrom G, Stavenow L, Janzon L, Lindgarde F, Hedblad B. Risk of myocardial infarction and stroke in smokers is related to plasma levels of inflammation-sensitive proteins. Arterioscler Thromb Vasc Biol 2004; 24: 577-582.
32. Engstrom G, Hedblad B, Eriksson KF, Janzon L, Lindgarde F. Complement C3 is a risk factor for the development of diabetes: a population-based cohort study. Diabetes 2005; 54: 570-575.
33. Broekhuizen R, Wouters EF, Creutzberg EC, Schols AM. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax 2006; 61: 17-22.
34. MacKenzie KE, Wiltshire EJ, Pena AS et al. Hs-CRP is associated with weight, BMI, and female sex but not with endothelial function in children with type 1 diabetes. Pediatr Diabetes 2009; 10: 44-51.
35. Festa A, D'Agostino R Jr, Williams K et al. The relation of body fat mass and distribution to markers of chronic inflammation. Int J Obes Relat Metab Disord 2001; 25: 1407-1415.
36. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796-1808.
37. Filley GF, Beckwitt HJ, Reeves JT, Mitchell RS. Chronic obstructive bronchopulmonary disease. II. Oxygen transport in two clinical types. Am J Med 1968; 44: 26-38.
38. Guerra S, Sherrill DL, Bobadilla A, Martinez FD, Barbee RA. The relation of body mass index to asthma, chronic bronchitis, and emphysema. Chest 2002; 122: 1256-1263.
39. Schols AM, Broekhuizen R, Weling-Scheepers CA, Wouters EF. Body composition and mortality in chronic obstructive pulmonary disease. Am J Clin Nutr 2005; 82: 53-59.
40. Ischaki E, Papatheodorou G, Gaki E, Papa I, Koulouris N, Loukides S. Body mass and fat-free mass indices in COPD: relation with variables expressing disease severity. Chest 2007; 132: 164-169.
41. Tomoda K, Yoshikawa M, Itoh T et al. Elevated circulating plasma adiponectin in underweight patients with COPD. Chest 2007; 132: 135-140.
42. Donaldson GC, Seemungal TA, Patel IS et al. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest 2005; 128: 1995-2004.